



## **Molecular Partners to hold oral presentations on DLL3-targeting Radio-DARPin candidate MP0712 at multiple upcoming scientific conferences**

May 4, 2026

ZURICH-SCHLIEREN, Switzerland and Concord, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- [Molecular Partners](#) AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics, today announced its attendance and presentations on its lead Radio-DARPin candidate MP0712 at upcoming scientific conferences.

### **Details of the events:**

#### **NIH National Cancer Institute 2026 Small Cell Lung Cancer Consortium Meeting**

May 6–7, Rockville, MD, USA

Title: Molecular characteristics of MP0712, a clinical stage <sup>212</sup>Pb-based Radio-DARPin candidate for targeted anti-DLL3 radiotherapy of small cell lung cancer (SCLC)

Session: New Therapy Targets

Date & Time: 7 May 2026; 10:30–10:45 am local time

#### **22<sup>nd</sup> Annual PEGS Boston**

May 11–15, Boston, MA, USA

Title: Advancing Radio-DARPin therapeutics: from preclinical insights to clinical development

Session: Novel Platforms and Preclinical-to-Clinical Strategies

Date & Time: 13 May 2026; 2:40–3:10 pm local time

#### **Antibody & Engineering Therapeutics**

May 27–29, Basel, Switzerland Title: Radio-DARPins for targeted alpha therapy: first in human insights with MP0712 and opportunities for future candidates

Track: ADCs & Bioconjugates – Advancing ADCs to the Clinic

Date & Time: 29 May 2026; 4:45–5:15 pm local time

#### **About Molecular Partners AG**

Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN) is a clinical-stage biotech company pioneering a novel class of protein drugs known as DARPins therapeutics, for medical challenges other treatment modalities cannot readily address. Molecular Partners leverages the key properties of DARPins to design and develop differentiated therapeutics for cancer patients, including targeted radiopharmaceuticals and next-generation immune cell engagers. The Company has proprietary programs in various stages of pre-clinical and clinical development, as well as programs developed through partnerships with leading pharmaceutical companies and academic centers. Molecular Partners, founded in 2004, has offices in both Zurich, Switzerland and Concord, MA, USA. For more information, visit [www.molecularpartners.com](http://www.molecularpartners.com) and find us on LinkedIn and Twitter / X @MolecularPrtnrs

#### **For further details, please contact:**

Seth Lewis, EVP Corporate Finance

Concord, Massachusetts, U.S.

[seth.lewis@molecularpartners.com](mailto:seth.lewis@molecularpartners.com)

Tel: +1 781 420 2361

Laura Jeanbart, PhD, Head of Portfolio Management & Communications

Zurich-Schlieren, Switzerland

[laura.jeanbart@molecularpartners.com](mailto:laura.jeanbart@molecularpartners.com)

Tel: +41 44 575 19 35

#### **Cautionary Note Regarding Forward-Looking Statements**

This press release contains forward-looking statements. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, as amended, including without limitation: implied and express statements regarding the clinical development of Molecular Partners' current or future product candidates; expectations regarding timing for reporting data from ongoing clinical trials or the initiation of future clinical trials; the potential therapeutic and clinical benefits of Molecular Partners' product candidates and its RDT and Switch-DARPin platforms; the selection and development of future programs; Molecular Partners' collaboration with Orano Med including the benefits and results that may be achieved through the collaboration; the expected benefits of the strategic review; and Molecular Partners' expected business and financial outlook, including anticipated expenses and cash utilization for 2026 and its expectation of its current cash runway. These statements may be identified by words such as "aim", "anticipate", "expect", "guidance", "intend", "outlook", "plan", "potential", "will" and similar expressions, and are based on Molecular Partners' current beliefs and expectations. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Some of the key factors that could cause actual results to differ from Molecular Partners' expectations include, but are not limited to, those set forth in under the heading "Risk Factors" in Molecular Partners' Annual Report on Form 20-F for the year ended December 31, 2025 and other filings Molecular Partners makes with the SEC from time to time. These documents are available on the Investors page of Molecular Partners' website at [www.molecularpartners.com](http://www.molecularpartners.com). In addition, this press release contains information relating to interim data as of the relevant data cutoff date, results of which may differ from topline results that may be obtained in the future.

Any forward-looking statements speak only as of the date of this press release and are based on information available to Molecular Partners as of the date of this release, and Molecular Partners assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.